title: Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases.
authors.affiliation: Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: O
authors.initials: O
authors.lastname: Kanai
authors.affiliation: Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Fujita
authors.affiliation: Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Okamura
authors.affiliation: Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Nakatani
authors.affiliation: Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan tabomio@gmail.com.
authors.forename: T
authors.initials: T
authors.lastname: Mio
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000077594:Nivolumab; D012720:Severity of Illness Index
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab